May 6th 2024
Analysis reveals rising hospitalization rates among pregnant women with hepatitis C virus (HCV) and age as a critical factor influencing maternal and fetal health outcomes.
Egyptian Initiative Aims to Create “A World Free of Hepatitis C”
March 10th 2017According to Tour n’ Cure, an Egyptian initiative that aims to rid the world of hepatitis C, Egypt aims to give program participants an opportunity to receive full treatment at an extremely low cost, while touring “the land that gave birth to the first great civilization.”
Read More
Merck Loses Big Money on HCV Drug
March 4th 2017Kenilworth, New Jersey-based Merck, will take a loss of $0.22 a share from last year’s fourth quarter. This will account for a total loss of $2.9 billion, or $1.9 billion after taxes. The pharmaceutical giant had previously reported a profit of $0.42 a share for that period.
Read More
The Missing Link in Eliminating Viral Hepatitis B & C
February 28th 2017Elimination of viral hepatitis depends on individuals actively participating in their own healthcare and management. They can only do this if they understand why and how to protect their miraculous, life-sustaining liver from harm. Education is the key to prevention.
Read More
Does Race or Ethnicity Impact the Efficacy of DAAs for the Treatment of HCV?
February 22nd 2017Researchers recently examined data from 21k+ patients in the Veterans Affairs healthcare system to determine if a correlation exists between race or ethnicity and the efficacy of direct-acting antiviral (DAAs) for the treatment of hepatitis C (HCV).
Read More
Reducing the Incidence of Acute Kidney Injury from Vancomycin & Pip/Tazo
February 9th 2017Megan Luther, PharmD, Advanced Health Services research fellow, Providence Veterans Affairs Medical Center, University of Rhode Island, College of Pharmacy, discusses potential strategies to reduce incidence of acute kidney injuries due to vancomycin and pip/tazo combination therapy.
Watch
Direct-Acting Antivirals for HCV-Associated Rheumatic Diseases
February 1st 2017In a review article published in Rheumatic Disease Clinics of North America, researchers discuss the main rheumatologic diseases associated with chronic HCV infection, and how DAAs have affected these extrahepatic manifestations.
Read More
Treatment Options for HCV Patients with Renal Impairment
February 1st 2017A research group from Hokkaido University in Japan found that standard treatment for those with genotype 1 HCV should likely be switched from interferon (INF)-based therapies to INF-free direct-acting antiviral (DAA) therapies.
Read More
Too Many Conflicts of Interest Found in HCV Management Guidelines
January 29th 2017A group of researchers recently published a study in JAMA, examining conflicts of interest (COIs) among committee members who set hepatitis C (HCV) and cholesterol management guidelines. They found that there, in fact, were COIs among committee members setting HCV management guidelines.
Read More
HCV Treatment Achieves Viral Suppression in Less Than 12 Weeks
January 24th 2017Researchers conducted a post hoc analysis to learn whether or not the length of time it took to attain initial viral suppression is related to sustained virologic response (SVR) rates for patients receiving the so-call 3D treatment, with or without ribavirin.
Read More